Please enter the email address you used to register, then we will send you a link to choose a new password
HC Wainwright & Co. analyst Joseph Pantginis maintains Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and raises the pr...
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of ...
HC Wainwright & Co. analyst Matthew Kelsey assumes Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces ...
Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate...
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial ...